hVEGF-IN-1
目录号 : GC32963
hVEGF-IN-1是一种喹唑啉衍生物（IRES-A：Kd = 0.928μM)。
Cas No.:1637443-98-1
Sample solution is provided at 25 µL, 10mM.
hVEGF-IN-1 is a quinazoline derivative (IRES-A: Kd = 0.928μM) [1]. By reducing VEGF-A protein expression, hVEGF-IN-1 effectively blocks tumor cell migration and inhibits tumor growth [2]. hVEGF-IN-1 is primarily used to study VEGF-A-mediated tumor angiogenesis [3].
In MDA-MB-231 cells, hVEGF-IN-1 (0.375-3μM; 24h) reduced cell migration by approximately 25% [1]. In K562 cells, hVEGF-IN-1 (5μM; 24h) upregulates the expression of miR-let-7a and inhibits the translation of VEGF-A [4]. In NRK52E cells, hVEGF-IN-1 (5μM; 4h) inhibits VEGF-A expression [5].
References:
[1]. Wang S K, Wu Y, Wang X Q, et al. Discovery of Small Molecules for Repressing Cap-Independent Translation of Human Vascular Endothelial Growth Factor (h VEGF) as Novel Antitumor Agents[J]. Journal of Medicinal Chemistry, 2017, 60(13): 5306-5319.
[2]. Donlic A, Comi T J, Quinodoz S A, et al. Deep Learning of Functional Perturbations from Condensate Morphology[J]. bioRxiv, 2025: 2025.08. 18.670955.
[3]. Wu S, Wang N, Zhao L. Network pharmacology reveals the mechanism of activity of tongqiao huoxue decoction extract against middle cerebral artery occlusion-induced cerebral ischemia-reperfusion injury[J]. Frontiers in Pharmacology, 2021, 11: 572624.
[4]. Guo L, Lu T, Wang Y, et al. Inhibition of Acute Myeloid Leukaemia Development by Bittersweet Based on miR-let-7a Regulating Vascular Endothelial Growth Factor A Resistance Mechanism[J]. Journal of Biobased Materials and Bioenergy, 2024, 18(6): 1062-1068.
[5]. Lou Z, Li Q, Wang C, et al. The effects of microRNA-126 reduced inflammation and apoptosis of diabetic nephropathy through PI3K/AKT signalling pathway by VEGF[J]. Archives of physiology and biochemistry, 2022, 128(5): 1265-1274.
hVEGF-IN-1是一种喹唑啉衍生物（IRES-A：Kd = 0.928μM) [1]。通过降低VEGF-A蛋白表达，hVEGF-IN-1可有效阻断肿瘤细胞迁移并抑制肿瘤生长 [2]。hVEGF-IN-1主要用于研究VEGF-A介导的肿瘤血管生成 [3]。
在MDA-MB-231细胞中，hVEGF-IN-1（0.375-3μM；24h）使细胞迁移率降低了约25% [1]。在K562细胞中，hVEGF-IN-1（5μM；24h）上调miR-let-7a的表达并抑制VEGF-A的翻译 [4]。在NRK52E细胞中，hVEGF-IN-1（5μM；4h）抑制VEGF-A的表达 [5]。
| Cell experiment [1]: | |
Cell lines | MDA-MB-231 cells |
Preparation Method | MDA-MB-231 cells (5 × 104 cells, 100μL) were plated in the top chambers of 0.8μm pore trans-wells in Opti-MEM reduced serum medium in the presence or absence of hVEGF-IN-1. Meanwhile, 600μL of DMEM containing 10% fetal bovine serum (FBS) and 100μM CoCl2 were added to the lower chambers. The cells were allowed to migrate for 24h. At the end of the assay, the cells in the top chamber were removed, and the cells at the bottom of the filter were treated by adding 500μL of DMEM containing 2.5mg/mL 3-(4,5)-dimethylthiazol(-z-y1)-3,5-diphenyl tetrazolium bromide (MTT) to each well. After incubating at 37℃ with 5% CO2 for 4h, 500μL of DMSO was added to each well and the plate was gently rotated for 10min. Absorbance (570nm) was measured using a microplate reader. |
Reaction Conditions | 0.375-3μM; 24h |
Applications | hVEGF-IN-1 reduced cell migration by approximately 25%. |
References: | |
| Cas No. | 1637443-98-1 | SDF | |
| Canonical SMILES | CCN(CC)CCOC(C=C1)=CC=C1NC2=NC(C3=C(NC(CCN4CCN(C)CC4)=O)C=CC=C3)=NC5=CC=CC=C52 | ||
| 分子式 | C34H43N7O2 | 分子量 | 581.75 |
| 溶解度 | DMSO : 25 mg/mL (42.97 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.719 mL | 8.5948 mL | 17.1895 mL |
| 5 mM | 0.3438 mL | 1.719 mL | 3.4379 mL |
| 10 mM | 0.1719 mL | 0.8595 mL | 1.719 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet